NVENTA ANNOUNCES $8.6 MILLION CLOSING OF SHORT FORM PROSPECTUS OFFERING

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

FOR IMMEDIATE RELEASE - August 22, 2007

San Diego, California USA - Nventa Biopharmaceuticals Corporation (TSX: NVN) announces the successful completion today of the closing of its short form prospectus offering of units, resulting in the sale of 68,908,400 units at $0.125 per unit, for gross proceeds of $8,613,550.  Each unit consists of one common share of NVN and one-half of one transferable common share purchase warrant.  Each warrant entitles its holder to subscribe for one common share at any time before 5:00p.m. (Vancouver time) on February 22, 2010, at an exercise price of $0.25, subject to Nventa’s right to accelerate the expiry date in the event that the price of Nventa’s common shares closes at or above $0.625 for 20 consecutive trading days on the Toronto Stock Exchange.

The securities offered under this short form prospectus have not been and will not be registered under the United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to persons in the United States unless registered or an exemption from such registration is available.

About Nventa Biopharmaceuticals Corporation:

Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV).  The corporation is publicly traded on the Toronto Stock Exchange under the symbol NVN.

Contact:

Download a PDF file of this release